Concepts (52)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 3 | 2022 | 37 | 2.280 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 61 | 1.000 |
Why?
|
| Exosomes | 1 | 2022 | 6 | 0.850 |
Why?
|
| Neoplasms | 1 | 2022 | 54 | 0.810 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 6 | 0.760 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 12 | 0.760 |
Why?
|
| Furans | 1 | 2020 | 5 | 0.750 |
Why?
|
| Lignans | 1 | 2020 | 5 | 0.750 |
Why?
|
| Tumor Burden | 1 | 2020 | 15 | 0.740 |
Why?
|
| Inflammation | 1 | 2020 | 44 | 0.740 |
Why?
|
| Adipose Tissue | 1 | 2020 | 42 | 0.730 |
Why?
|
| Obesity | 1 | 2020 | 102 | 0.670 |
Why?
|
| Humans | 5 | 2022 | 2493 | 0.530 |
Why?
|
| Animals | 4 | 2022 | 1238 | 0.490 |
Why?
|
| Male | 3 | 2022 | 1649 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 25 | 0.230 |
Why?
|
| Phytochemicals | 1 | 2022 | 4 | 0.230 |
Why?
|
| Hormones | 1 | 2022 | 12 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 21 | 0.220 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 143 | 0.220 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 138 | 0.220 |
Why?
|
| Ligands | 1 | 2022 | 15 | 0.220 |
Why?
|
| Models, Biological | 1 | 2022 | 43 | 0.210 |
Why?
|
| MicroRNAs | 1 | 2022 | 41 | 0.200 |
Why?
|
| Mice | 2 | 2020 | 508 | 0.200 |
Why?
|
| Apoptosis | 1 | 2022 | 162 | 0.200 |
Why?
|
| Adipokines | 1 | 2020 | 3 | 0.190 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 9 | 0.190 |
Why?
|
| Prostate | 1 | 2020 | 10 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2020 | 19 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 33 | 0.190 |
Why?
|
| Adipocytes | 1 | 2020 | 26 | 0.190 |
Why?
|
| Cytokines | 1 | 2020 | 47 | 0.180 |
Why?
|
| Transcription Factors | 1 | 2020 | 42 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 118 | 0.180 |
Why?
|
| Diet, High-Fat | 1 | 2020 | 54 | 0.180 |
Why?
|
| Cell Proliferation | 1 | 2020 | 110 | 0.170 |
Why?
|
| Protein Phosphatase 2C | 1 | 2018 | 5 | 0.170 |
Why?
|
| Curcumin | 1 | 2018 | 7 | 0.170 |
Why?
|
| Glucose | 1 | 2018 | 39 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 45 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 167 | 0.140 |
Why?
|
| Models, Molecular | 1 | 2018 | 3 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 7 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 36 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 20 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2018 | 26 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 50 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2018 | 68 | 0.040 |
Why?
|
| Female | 1 | 2018 | 1733 | 0.030 |
Why?
|